• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Inocras Closes $31M for Whole-Genome Bioinformatics Platform

by Fred Pennic 08/03/2026 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know

  • San Diego-based bioinformatics company Inocras Inc. closed an oversubscribed $31M Series B-3 financing round, bringing its total capital raised to approximately $100M.
  • The funding round was supported by strategic investors NDS Corporation and Aimed Bio Inc., alongside new investors IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, and Shinhan Securities.
  • Proceeds will fund the U.S. expansion of Inocras’s CLIA/CAP-certified whole-genome sequencing (WGS) and automated analytics infrastructure, transferring clinical models established across Asia.
  • Inocras’s proprietary suite includes CancerVision™ for comprehensive somatic and germline tumor profiling and MRDVision™ for ultra-sensitive, whole-genome molecular residual disease tracking.
  • The financing builds on real-world adoption across 100+ Asian cancer institutions and recent whole-genome research collaborations analyzing The Cancer Genome Atlas (TCGA) alongside the Broad Institute.

Automated Curation and Whole-Genome Analytics

The clinical oncology, precision diagnostics, and genomic bioinformatics sectors face a persistent operational challenge: the analytical ceiling of narrow gene panels. While targeted next-generation sequencing (NGS) panels capture common coding mutations, they frequently miss complex structural variants, non-coding driver alterations, and broader mutational signatures across the cancer genome.

As precision oncology moves toward comprehensive whole-genome interpretation, health systems require automated bioinformatics pipelines that translate billions of genomic data points into clinically actionable decisions without delaying patient treatment.

Leveraging extensive clinical adoption across Asia, the company is deploying the capital to build out its U.S. operational, commercial, and laboratory infrastructure. Inocras’s platform integrates automated interpretation algorithms with high-depth sequencing pipelines to streamline clinical decision support:

  • CancerVision™ Comprehensive Profiling: Analyzes paired somatic and germline whole-genome data to identify single-nucleotide variants (SNVs), indels, copy-number alterations (CNAs), complex structural variants (SVs), and non-coding alterations, alongside biomarkers such as tumor mutational burden (TMB) and homologous recombination deficiency (HRD).
  • MRDVision™ ctDNA Detection: Utilizes a whole-genome, panel-free circulating tumor DNA (ctDNA) tracking model to achieve ultra-sensitive molecular residual disease detection with limits of detection reaching down to 1 ppm.
  • Demonstrated Regional Footprint: Capitalizes on existing clinical usage across 100+ Asian cancer centers, supporting approximately 30 hospitals in South Korea and establishing a major commercial hub in Hong Kong.
  • Large-Scale Population Validation: Complements a recent collaboration with Broad Institute researchers analyzing thousands of TCGA cancer cases to establish standardized whole-genome curation benchmarks.

“We have already seen meaningful adoption across cancer institutions in Asia, where our technology has been used in thousands of patient cases,” stated Jehee Suh, Chief Executive Officer of Inocras.


As Inocras expands its CLIA/CAP-certified footprint into U.S. hospital networks, its whole-genome platform establishes a clear operational benchmark for how high-depth data automation will drive the future of precision oncology.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |